

Sarah P Blagden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1812818/publications.pdf>

Version: 2024-02-01

44
papers

1,757
citations

331259

21
h-index

315357

38
g-index

45
all docs

45
docs citations

45
times ranked

2914
citing authors

#	ARTICLE	IF	CITATIONS
1	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 2084-2095.	6.3	142
2	La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs. <i>ELife</i> , 2017, 6, .	2.8	136
3	The biological and therapeutic relevance of mRNA translation in cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 280-291.	12.5	131
4	Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1531-1542.	2.9	125
5	The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. <i>Nucleic Acids Research</i> , 2016, 44, 1227-1246.	6.5	120
6	Polar expeditions "provisioning the centrosome for mitosis. <i>Nature Cell Biology</i> , 2003, 5, 505-511.	4.6	116
7	The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. <i>Nucleic Acids Research</i> , 2010, 38, 5542-5553.	6.5	94
8	The La-Related Proteins, a Family with Connections to Cancer. <i>Biomolecules</i> , 2015, 5, 2701-2722.	1.8	90
9	A study of symptoms described by ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2012, 125, 59-64.	0.6	77
10	Drosophila Larp associates with poly(A)-binding protein and is required for male fertility and syncytial embryo development. <i>Developmental Biology</i> , 2009, 334, 186-197.	0.9	73
11	The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction. <i>Nucleic Acids Research</i> , 2021, 49, 458-478.	6.5	66
12	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1009-1016.	3.2	56
13	The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5' TOP sequence. <i>Nucleic Acids Research</i> , 2015, 43, 8077-8088.	6.5	55
14	Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 149.	1.3	52
15	Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells. <i>Developmental Cell</i> , 2020, 55, 298-313.e10.	3.1	50
16	Controversies around the function of LARP1. <i>RNA Biology</i> , 2021, 18, 207-217.	1.5	49
17	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1472-1478.	3.2	38
18	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. <i>British Journal of Cancer</i> , 2018, 119, 815-822.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. <i>Cancer Research</i> , 2021, 81, 1667-1680.	0.4	32
20	Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. <i>British Journal of Cancer</i> , 2020, 122, 473-482.	2.9	26
21	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. <i>BMC Cancer</i> , 2020, 20, 198.	1.1	25
22	Dose-Finding Quantitative ¹⁸ F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1828-1835.	2.8	24
23	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 969-977.	5.1	23
24	The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6500-6513.	3.2	16
25	The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 1570-1579.	3.2	12
26	LARP1 isoform expression in human cancer cell lines. <i>RNA Biology</i> , 2021, 18, 237-247.	1.5	11
27	A source of hope for platinum-resistant ovarian cancer?. <i>Lancet</i> , The, 2021, 397, 254-256.	6.3	11
28	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 919-930.	5.1	11
29	Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer. <i>Wiley Interdisciplinary Reviews RNA</i> , 2018, 9, e1432.	3.2	10
30	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020, 37, 61.	1.2	9
31	Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. <i>Journal of Medical Genetics</i> , 2021, 58, 392-399.	1.5	9
32	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. <i>Women's Health</i> , 2015, 11, 355-367.	0.7	8
33	New challenges in psycho-oncology: Using drug development methodology to improve survivorship and supportive care intervention trials. <i>Psycho-Oncology</i> , 2019, 28, 1362-1366.	1.0	6
34	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3028-3038.	3.2	4
35	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. <i>JCI Insight</i> , 2021, 6, .	2.3	3
36	Targeting MAPK in recurrent, low-grade serous ovarian cancer. <i>Lancet</i> , The, 2022, 399, 499-501.	6.3	3

#	ARTICLE	IF	CITATIONS
37	Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome. <i>Cancers</i> , 2022, 14, 1621.	1.7	3
38	Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738. , 2021, , .		1
39	Abstract CT136: NUC-7738, a novel ProTide transformation of 3'-deoxyadenosine, in patients with advanced solid tumors. , 2021, , .		1
40	PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2201-2203.	3.2	1
41	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
42	A decade of LARP society. <i>RNA Biology</i> , 2021, 18, 157-158.	1.5	0
43	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
44	CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CGE22-097.	2.3	0